April 22, 2025

Dual Therapy Lowers Death Risk in Diabetes Study

A large study found that combining GLP-1 receptor agonists with thiazolidinediones significantly reduced death and heart risks in patients with type 2 diabetes.

Conexiant

April 21, 2025

Risk-Free Midlife: 10+ Years Longer Living

Prioritizing the prevention and treatment of the modifiable risk factors could substantially extend healthy life expectancy worldwide.

Conexiant

April 17, 2025

Early Ezetimibe After MI Tied to Reduced MACE in SWEDEHEART Registry

Delaying ezetimibe use after MI was associated with worse outcomes in a Swedish national cohort study of 35,826 patients.

Conexiant

April 16, 2025

Newer Glucose-Lowering Drugs Reduce CV Events in Older Adults

"Use of GLP1-RAs and SGLT-2is was associated with reduced rates of 3P-MACE and HHF compared to DPP-4is, independent of age" - findings from a Danish nationwide study of 35,679 patients aged 70 and older with T2D.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

Tenecteplase Matches Alteplase in Stroke Outcomes

In a registry-based study of 79,550 patients, tenecteplase showed comparable short-term safety and effectiveness to alteplase for acute ischemic stroke, with no significant differences in functional outcomes or hemorrhagic events.

Conexiant

April 14, 2025

Pecans May Lower Cholesterol, Triglycerides

Replacing usual snacks with 57 g/d of pecans for 12 weeks improved lipids and diet quality.

Conexiant

April 14, 2025

1 in 5 Patients Face Stroke Within Decade After TIA

Meta-analysis of 171,000+ patients shows persistent long-term stroke risk following TIA, with half of recurrent events occurring after the first year.

Conexiant

April 11, 2025

Combination Lipid Therapy Lowers CV Risk

Meta-analysis shows a 19% reduction in all-cause mortality with combination lipid-lowering therapy vs statin monotherapy in high-risk patients.

Conexiant